European countries will have to cover reimbursement prices if the Oxford University coronavirus vaccine causes side effects, as part of the EU agreement to protect the experimental vaccine at a reduced price, it was said today.
The European Union has reportedly reached an agreement with AstraZeneca, which owns the experimental shooting rights, which reduces the duty of the British drug giant if others get sick after being vaccinated.
EU countries will pay the reduced value of EUR 2. 20 according to the dose of the Covid-19 vaccine once rigorous clinical trials are completed and the vaccine is considered through fitness regulators, probably in early 2021.
Britain has already received 100 million doses of the vaccine for an undisclosed amount, but AstraZeneca is expected to bear the price of negative side effects among the British.
The EU agreement reached in August, before complex trials of the vaccine were stopped before this month, when a British volunteer was hospitalised for severe swelling of the spine that was allegedly triggered by the blow.
But researchers found that there is no evidence that the patient’s condition is directly caused by the vaccine and trials restarted in the UK, Brazil, India and South Africa.
Unexpected side effects after a drug has been given the green light through medical regulators are rare because the approval procedure is very rigorous, but the rate at which the vaccine is deployed (vaccines take 10 to 15 years to expand) can increase the likelihood of unforeseen problems.
The British are entitled to a single tax-free payment of 120,000 euros if they are “severely disabled as a result of vaccination against certain diseases,” according to the government.
But patients have to prove in court that their condition is the direct result of a vaccine, which can be difficult.
The AstraZeneca candidate vaccine, known as AZD1222, is in Phase 3 trials, the last step before knowledge of protection and efficacy can be sent to regulators. Photo: Brazilian volunteer receiving Oxford vaccine, 24 July
Tests are underway to shoot with AstraZeneca in the United States, the United Kingdom, Australia, Brazil (pictured) and other countries. Phase 3 tests will now be suspended while security knowledge is reviewed.
The bloc paid about three hundred million pounds for 400 million doses of the Oxford vaccine in August, however, the settlement’s liability clauses had not been reported before.
An EU official, who asked to be identified, told Reuters that AstraZeneca would only pay legal fees up to a secure threshold under the terms of the agreement.
They refused to give the main points of the value cap or how prices would be shared with the various European governments.
By posting your comment, you settle for our internal rules.
We will post your comment and link to the story in your Facebook timeline at the same time as it will be posted on MailOnline. To do this, we will link your MailOnline account to your Facebook account. We’ll ask you to verify this for your first Facebook post.
You can use each post if you need it to be published on Facebook. Your facebook core points will be used to provide you with personalized content, marketing and advertising in accordance with our privacy policy.
Published through Associated Newspapers Ltd
Part of the Daily Mail, The Mail on Sunday and Metro Media Group